论文部分内容阅读
目的:研究妥洛特罗贴剂佐治喘息性疾病患儿临床疗效及对肺功能与免疫水平的影响。方法:按照随机编码顺序将81例轻、中度喘息性疾病患儿分为治疗组40例及对照组41例,两组均给予常规对症治疗;对照组加用沙丁胺醇联合雾化吸入,治疗组加用妥洛特罗贴,比较两组患儿临床疗效、咳嗽及喘鸣音持续时间、治愈天数,治疗7天后肺功能情况,血IgE值(TigE)及外周嗜酸性粒细胞(EOS)计数。结果:两组患儿临床疗效、咳嗽及喘鸣音持续时间、治愈天数比较差异均无统计学意义(P>0.05);治疗组治疗后肺功能改善情况、IgE水平和外周血EOS计数改善程度均优于对照组,差异有统计学意义(P<0.05)。结论:妥洛特罗贴剂佐治喘息性疾病患儿,可改善IgE水平和外周血EOS计数,提高患儿免疫水平。
OBJECTIVE: To study the clinical efficacy and safety of tulobuterol in treating asthmatic children with asthma and its effects on lung function and immunity. Methods: According to the random code sequence, 81 children with mild or moderate asthmatic disease were divided into treatment group (40 cases) and control group (41 cases). Both groups were given conventional symptomatic treatment. Patients in control group were treated with salbutamol combined with inhalation. The effect of cough and wheeze, the days of cure, lung function, blood IgE (TigE) and peripheral eosinophil count (EOS) were compared between the two groups after treatment with tulobuterol. . Results: There was no significant difference in clinical curative effect, duration of cough and wheeze, and days of cure between the two groups (P> 0.05). Improvement of pulmonary function, IgE level and EOS count of peripheral blood in the treatment group All were better than the control group, the difference was statistically significant (P <0.05). CONCLUSION: The use of tulobuterol adjuvant in children with asthmatic diseases can improve IgE levels and EOS count in peripheral blood and improve the immunity level in infants.